03 · What You Need to Know
Methods and analysis determine what the data can say
Funder involvement is not automatically methodological interference
Funders may possess expertise genuinely relevant to study design. A pharmaceutical company may know the pharmacology and manufacturing characteristics of its product. A technology company may understand how its system operates. A government agency may require standardized measures so findings can inform policy. A foundation may bring knowledge of the population it serves.
Researchers can use that expertise without surrendering scientific responsibility.
ICMJE does not require sponsors to disappear from the research process. Instead, it requires transparency about sources of support and the sponsor's role, if any, in study design, data collection, analysis and interpretation, report writing, and publication restrictions.
Control matters more than mere participation
There is an important difference between a sponsor proposing an analytic approach that investigators can evaluate and a sponsor dictating the only analysis researchers are permitted to see.
Collaborative involvement
The sponsor contributes expertise or analysis while investigators can scrutinize the methods, access appropriate data, challenge decisions, verify results, and report their interpretation honestly.
Problematic control
The sponsor determines consequential methodological or analytical choices without meaningful independent scrutiny or restricts investigators' ability to access data, conduct analysis, interpret findings, or publish results.
The distinction is not always binary. Research agreements can distribute authority in complicated ways. That is precisely why roles should be defined before the study begins rather than reconstructed after results become controversial.
Design choices can favor an outcome without fabricating any data
Research does not need falsified numbers to produce a misleading impression. Methodological decisions made before or during data collection can materially affect the comparison being tested.
In intervention research, relevant choices may include the comparator, dosage, inclusion and exclusion criteria, follow-up period, outcome definitions, timing of measurements, handling of protocol deviations, and sample size.
A sponsor might have defensible reasons for recommending any of these choices. The concern is whether they are scientifically justified or strategically selected to increase the likelihood of a favorable result.
This follows naturally from the earlier question of how funders can influence the research question. Once the question is chosen, methodological decisions determine how it will actually be answered.
Comparator choice deserves particular scrutiny
Suppose a new treatment is compared with a placebo even though an effective standard treatment exists. Or suppose it is compared with an alternative administered at a dose or schedule that does not reflect appropriate practice.
Such choices can affect how favorable the new intervention appears. They may sometimes be scientifically or ethically justified, but the justification matters.
The broader evidence on industry sponsorship illustrates why design-level scrutiny is important. A Cochrane methodological review found that industry-sponsored drug and medical-device studies were more likely to report sponsor-favorable efficacy results and conclusions than studies with other sponsorship, while the observed sponsorship association was not explained by several standard risk-of-bias domains.
This does not prove that comparator manipulation explains the association. It does suggest that evaluating sponsorship requires attention beyond a short conventional checklist.
Analytical flexibility creates many consequential choices
Even with a fixed dataset, researchers can make numerous analytical decisions. Which participants belong in the analysis? How will missing observations be handled? Which covariates will be included? Which statistical model will be used? Which time point is primary? Which subgroups will be examined?
Reasonable analysts can sometimes make different defensible choices. The risk increases when analysts repeatedly explore alternatives and preferentially report those producing the most favorable result.
Prespecifying important analyses can reduce this flexibility. It does not prohibit exploratory analysis. Instead, it allows readers to distinguish analyses planned before seeing the results from those developed afterward.
Current ICMJE recommendations specifically state that reports should distinguish prespecified from exploratory analyses, including subgroup analyses. They also call for statistical methods to be described in sufficient detail for a knowledgeable reader with access to the data to judge their appropriateness and verify the reported results.
Sponsor statisticians can participate without making the analysis inherently invalid
A statistical analysis does not become wrong simply because the analyst works for the sponsor. Company statisticians may be highly qualified and may have legitimate responsibilities in the research.
Employment does, however, create a relevant relationship that should be transparent. More importantly, academic or other responsible authors should understand the analysis sufficiently to take responsibility for the claims they publish.
A manuscript should not function as a relay system in which investigators receive tables from the sponsor and attach their names without meaningful access to the underlying evidence or analytical process.
Data access determines whether independent scrutiny is possible
Analytical independence becomes difficult if investigators cannot access the data underlying the analysis.
ICMJE's 2026 recommendations explicitly require reporting whether authors had access to study data and the nature and extent of that access. ICMJE also states that authors should avoid sponsor agreements that interfere with access to all study data or with their ability to analyze, interpret, prepare, and publish manuscripts independently.
WHO's Bulletin similarly asks authors to affirm that they have not entered an agreement with a funder limiting their ability to complete the research as planned and to indicate that they had full control of primary data.
The separate question of who should control data in sponsor-funded research therefore has direct implications for analytical independence.
Independent analysis can be a useful safeguard
When the sponsor has a strong proprietary interest, independent statistical analysis or verification can reduce dependence on the sponsor's interpretation. This may involve academic statisticians, an independent data center, or another arrangement appropriate to the project.
Independent analysis is not a magical certificate of validity. Analysts can make mistakes regardless of employer. Nor is it necessary in every funded study.
Its value is structural: it gives the research team and readers greater confidence that the published findings do not depend entirely on analytical decisions made by the party with the strongest financial interest in the result.
Changing the analysis after seeing the data requires transparency
Research plans sometimes need legitimate modification. Unexpected distributions, measurement problems, assumption violations, recruitment difficulties, or newly recognized scientific issues can require changes.
The ethical problem is not modification itself. It is silently presenting a post hoc choice as though it had been prespecified, particularly when the change was selected because it produced a more desirable result.
Researchers should document substantial deviations from the planned analysis, explain them where relevant, and distinguish confirmatory from exploratory work.
The sponsor should not control the conclusion by controlling the analysis
ICMJE's longstanding position is that authors should avoid agreements interfering with their ability to analyze and interpret study data independently and prepare and publish manuscripts. It also recommends reporting the sponsor's role in analysis and interpretation.
This does not mean investigators must reject every interpretation proposed by a sponsor. It means the sponsor should not have exclusive authority to determine what the data are allowed to mean.
Methodological transparency helps readers evaluate sponsor influence
Clear protocols, trial registration where applicable, statistical analysis plans, detailed methods, reporting guidelines, data-access statements, and disclosure of sponsor roles can make sponsor influence more visible and research decisions more auditable.
ICMJE's current guidance emphasizes that methods should explain how and why a study was conducted in a particular way and should provide enough detail to enable reproduction of the results by others with access to the data.
Transparency does not prevent every questionable decision. It makes those decisions harder to hide and easier to evaluate.
07 · A Quick Checklist
What should you verify before accepting sponsor involvement in methods or analysis?
Before agreeing to the methodological and analytical arrangement, check:
Define who has authority over the protocol, comparator, outcomes, eligibility criteria, measurements, and other consequential design decisions.
Prespecify primary outcomes and important analyses when appropriate to the study design.
Clarify who will conduct the primary analysis and whether independent verification is possible.
Ensure responsible investigators have appropriate access to the data and analytical documentation needed to evaluate the results they publish.
Require substantial deviations from planned analyses to be documented and scientifically justified.
Distinguish prespecified analyses from exploratory and post hoc analyses in the manuscript.
Disclose the sponsor's actual role in study design, data collection, analysis, interpretation, and manuscript preparation.
Confirm that investigators remain free to report scientifically defensible findings and interpretations even when the sponsor disagrees.
